SCHEMBL2864756

SCHEMBL2864756

CCCCCCn1c(=O)n(CCCNCCCCNCCCn2c(=O)c3ccccc3n(CCCCCC)c2=O)c(=O)c2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.65
PGR P06401 1/20 0.56
RORA P35398 1/20 0.56
RORC P51449 1/20 0.56
RORB Q92753 1/20 0.56
KDM4E B2RXH2 4/20 0.52
MAPT P10636 1/20 0.52
RXFP1 Q9HBX9 1/20 0.51
MAPK1 P28482 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
THRB P10828 1/20 0.50
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
HTT P42858 1/20 0.49
TP53 P04637 1/20 0.48
ALDH1A1 P00352 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417860 0.90 CNR2 (0.68) CNR2PGRRORARORCRORB
SCHEMBL3761737 0.85 HDAC1 (0.59) CNR2PGRRORARORCRORB
SCHEMBL2858305 0.82 TNF (0.59) CNR2PGRRORARORCRORB
SCHEMBL30484777 0.80 CNR2 (0.56) CNR2PGRRORARORCRORB
SCHEMBL30484776 0.80 CNR2 (0.56) CNR2PGRRORARORCRORB
SCHEMBL25316072 0.80 CNR2 (0.56) CNR2PGRRORARORCRORB
SCHEMBL28002722 0.80 CNR2 (0.56) CNR2PGRRORARORCRORB
SCHEMBL8862370 0.80 CNR2 (0.56) CNR2PGRRORARORCRORB
SCHEMBL25318908 0.80 CNR2 (0.56) CNR2PGRRORARORCRORB
SCHEMBL6454733 0.79 CNR2 (0.56) CNR2PGRRORARORCRORB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US claimed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US claimed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US claimed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP claimed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US claimed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP claimed
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US disclosed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US disclosed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US disclosed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP disclosed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US disclosed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME AQP4, PMP22, CNTN1 CNR2 179/4885PGR 4661/4885RORA 3928/4885
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same AQP4, PMP22, CNTN1 CNR2 179/4885PGR 4661/4885RORA 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.